Literature DB >> 28008570

The role of interventional radiology in the treatment of intrahepatic cholangiocarcinoma.

Anna Maria Ierardi1, Salvatore Alessio Angileri2, Francesca Patella2, Silvia Panella2, Natalie Lucchina1, Elena N Petre3, Antonio Pinto4, Giuseppe Franceschelli5, Gianpaolo Carrafiello2, Gianpaolo Cornalba6, Constantinos T Sofocleous3.   

Abstract

Intrahepatic cholangiocarcinoma (ICC) is the second most common primary hepatic malignancy after hepatocellular carcinoma. Complete surgical resection remains the only potentially curative option for patients with ICC. However, until now, early diagnosis with potential surgical intervention has been the exception rather than the rule with only 30% of patients qualifying for attempted surgical cure. Many patients are unresectable because of disease stage, anatomic conditions, medical comorbidities, and small future remnant liver. Interventional radiology procedures are available for these types of patients with intra-arterial therapies and/or ablative treatments both for curative and for palliative treatment. The goals of interventional therapy are to control local tumor growth, to relieve symptoms, and to improve and preserve quality of life. The choice of treatment depends largely on tumor extent and patient performance. No randomized studies exist to compare treatments. The present review describes the current evidence of the interventional treatments in the management of the ICC. Moreover, interventional procedures available to increase the future liver reserve before surgery were analyzed.

Entities:  

Keywords:  Ablative treatments; Interventional radiology; Intra-arterial therapies; Intrahepatic cholangiocarcinoma; Palliative treatment; Radioembolization

Mesh:

Year:  2016        PMID: 28008570     DOI: 10.1007/s12032-016-0866-1

Source DB:  PubMed          Journal:  Med Oncol        ISSN: 1357-0560            Impact factor:   3.064


  71 in total

Review 1.  Liver transplantation for cholangiocarcinoma.

Authors:  Charles B Rosen; Julie K Heimbach; Gregory J Gores
Journal:  Transpl Int       Date:  2010-05-20       Impact factor: 3.782

Review 2.  Hilar cholangiocarcinoma.

Authors:  Victor M Zaydfudim; Charles B Rosen; David M Nagorney
Journal:  Surg Oncol Clin N Am       Date:  2014-04       Impact factor: 3.495

Review 3.  Radiofrequency ablation in the treatment of unresectable intrahepatic cholangiocarcinoma: systematic review and meta-analysis.

Authors:  Kichang Han; Heung Kyu Ko; Kyung Won Kim; Hyung Jin Won; Yong Moon Shin; Pyo Nyun Kim
Journal:  J Vasc Interv Radiol       Date:  2015-04-18       Impact factor: 3.464

4.  Prognostic value of cirrhosis for intrahepatic cholangiocarcinoma after surgical treatment.

Authors:  Ya-yong Li; Hao Li; Pin Lv; Gang Liu; Xiao-rong Li; Bu-ning Tian; Dao-jin Chen
Journal:  J Gastrointest Surg       Date:  2011-01-19       Impact factor: 3.452

5.  Radiofrequency ablation of intrahepatic cholangiocarcinoma: preliminary experience.

Authors:  Gianpaolo Carrafiello; Domenico Laganà; Elisa Cotta; Monica Mangini; Federico Fontana; Francesca Bandiera; Carlo Fugazzola
Journal:  Cardiovasc Intervent Radiol       Date:  2010-04-22       Impact factor: 2.740

Review 6.  Intrahepatic cholangiocarcinoma: macroscopic type and stage classification.

Authors:  Susumu Yamasaki
Journal:  J Hepatobiliary Pancreat Surg       Date:  2003

Review 7.  Intrahepatic Cholangiocarcinoma.

Authors:  Siddharth A Padia
Journal:  Tech Vasc Interv Radiol       Date:  2015-07-15

Review 8.  Assessment of liver tumor response to therapy: role of quantitative imaging.

Authors:  Fernanda D Gonzalez-Guindalini; Marcos P F Botelho; Carla B Harmath; Kumaresan Sandrasegaran; Frank H Miller; Riad Salem; Vahid Yaghmai
Journal:  Radiographics       Date:  2013-10       Impact factor: 5.333

9.  Transarterial chemoembolization (TACE) for inoperable intrahepatic cholangiocarcinoma.

Authors:  S Herber; G Otto; J Schneider; N Manzl; I Kummer; S Kanzler; A Schuchmann; J Thies; C Düber; M Pitton
Journal:  Cardiovasc Intervent Radiol       Date:  2007-05-17       Impact factor: 2.740

10.  OEM-TACE: a new therapeutic approach in unresectable intrahepatic cholangiocarcinoma.

Authors:  Guido Poggi; A Amatu; B Montagna; P Quaretti; C Minoia; C Sottani; L Villani; B Tagliaferri; F Sottotetti; O Rossi; E Pozzi; F Zappoli; A Riccardi; G Bernardo
Journal:  Cardiovasc Intervent Radiol       Date:  2009-11       Impact factor: 2.740

View more
  6 in total

1.  Locoregional therapies in cholangiocarcinoma.

Authors:  Peter L Labib; Brian R Davidson; Ricky A Sharma; Stephen P Pereira
Journal:  Hepat Oncol       Date:  2017-11-17

Review 2.  Treatment of Primary Liver Tumors and Liver Metastases, Part 2: Non-Nuclear Medicine Techniques.

Authors:  Francois H Cornelis; Stephen B Solomon
Journal:  J Nucl Med       Date:  2018-10-25       Impact factor: 10.057

3.  Chemoembolization versus radioembolization for the treatment of unresectable intrahepatic cholangiocarcinoma in a single institution image-based efficacy and comparative toxicity.

Authors:  Olaguoke Akinwande; Veer Shah; Abigail Mills; Christopher Noda; Eric Weiner; Gretchen Foltz; Nael Saad
Journal:  Hepat Oncol       Date:  2017-10-30

Review 4.  CT-MRI LI-RADS v2017: A Comprehensive Guide for Beginners.

Authors:  Francesca Patella; Filippo Pesapane; Enrico Maria Fumarola; Ilaria Emili; Riccardo Spairani; Salvatore Alessio Angileri; Silvia Tresoldi; Giuseppe Franceschelli; Gianpaolo Carrafiello
Journal:  J Clin Transl Hepatol       Date:  2018-02-22

5.  Role of 3D quantitative tumor analysis for predicting overall survival after conventional chemoembolization of intrahepatic cholangiocarcinoma.

Authors:  Irvin Rexha; Fabian Laage-Gaupp; Julius Chapiro; Milena Anna Miszczuk; Johanna Maria Mijntje van Breugel; MingDe Lin; Menelaos Konstantinidis; Rafael Duran; Bernhard Gebauer; Christos Georgiades; Kelvin Hong; Nariman Nezami
Journal:  Sci Rep       Date:  2021-04-29       Impact factor: 4.379

6.  One case of iodine-125 therapy - A new minimally invasive treatment of intrahepatic cholangiocarcinoma.

Authors:  Xinju Chen; Xiaoqi Chen; Chuanlei Zhang; Xinting Wang; Changwei Yuan; He Yang; Lixia Yang
Journal:  Open Life Sci       Date:  2022-09-27       Impact factor: 1.311

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.